Onkologie Erding

The medical center is at the forefront of research into Polycythemia Vera, focusing on innovative approaches to understand and manage this condition. The center's work is particularly distinguished by its use of artificial intelligence to predict resistance to hydroxyurea (HU) treatment, a common therapeutic approach for this disease.

• Artificial Intelligence in Predictive Medicine
• Hydroxyurea Resistance Mechanisms
• Advanced Therapeutic Strategies

By integrating machine learning techniques, the center is pioneering new predictive models that enhance the personalization of treatment plans, potentially improving outcomes for patients with Polycythemia Vera.

Specializing in Myelofibrosis, the center is conducting cutting-edge research to explore novel therapeutic combinations. The focus is on the safety and efficacy of BMS-986158 in combination with established treatments like Ruxolitinib and Fedratinib, particularly for patients with intermediate or high-risk profiles.

• Combination Therapy Efficacy
• Safety and Tolerability Assessments
• Advanced Risk Stratification

Through these studies, the center aims to refine treatment protocols and expand therapeutic options, offering hope for improved management of Myelofibrosis in diverse patient populations.